- AdventHealth Research Institute
A new study reveals that people newly diagnosed with Type 2 diabetes face a significantly higher risk of developing aggressive cancers—including those of the liver, pancreas, and colon.
While obesity has long been linked to these cancers, the research suggests Type 2 diabetes itself may be an independent driver of cancer risk. The findings, presented at the 2025 European Congress on Obesity, analyzed data from over 23,000 people in the U.K. Biobank with new-onset Type 2 diabetes and compared them to more than 71,000 non-diabetic individuals of similar age, sex, and weight.
Over five years, cancer risk was clearly higher in the diabetes group:
- Liver cancer risk was nearly 4 times higher in men and 5 times higher in women.
- Pancreatic cancer risk rose 74% in men, nearly doubled in women.
- Colorectal cancer risk increased by more than 25% in both groups.
Lead author Owen Tipping from the University of Manchester said the link may stem from factors like inflammation, insulin resistance, or gut microbiome changes—beyond just excess weight.
Experts say more research is needed but agree the findings highlight the importance of early detection, healthy lifestyle changes, and ongoing monitoring. “This isn’t a reason to panic,” said oncologist Dr. Jack Jacoub. “It’s a reason to take action—through diet, exercise, and good blood sugar control.”
The takeaway? Type 2 diabetes may do more than disrupt blood sugar—it could quietly raise your cancer risk too.
Recent News
In our latest Clinician’s View, Dr. Seminerio shares her personal passion for improving care for patients with inflammatory bowel disease (IBD) and talks about how AdventHealth’s recently established...
Under the leadership of Principal Investigator Valeria Baldivieso, MD, and Sub-Investigator Chandan Reddy, MD, MS, FAANS, the AdventHealth Research Institute is recruiting patients for the Exablate...
New Study Published in the New England Journal of Medicine Shows the Addition of Regional Nodal Irradiation Does Not Decrease Rate of Invasive Breast Cancer Recurrence in Patients with Negative...
For people with Type 1 diabetes (T1D), low blood sugar episodes—also known as hypoglycemia—can strike fast and hard. The body’s natural defense is to release hormones like glucagon to raise blood...
Dr. Richard Pratley, Samuel E. Crockett Chair in Diabetes Research and Medical Director of AdventHealth Diabetes Institute, recently shared insights with Healio Endocrinology about the importance of...
Under the leadership of principal investigator Michael Seidman, MD, AdventHealth Research Institute is participating in the multi-site Clinical Trial of Etanercept (TNF-alpha Blocker) for Treatment of...
Metabolic dysfunction associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), affects about 70% of people with type 2 diabetes, placing them at...
Dr. Kirk Erickson Joins the NavNeuro Podcast to Discuss the Connection Between Physical Activity and Brain Health
Results From IGNITE Research Study Published in the Medical Journal "Age and Ageing"
“We are at a pivotal point in our understanding of neuroscience and in particular, neuroplasticity – the ability of neural networks in the brain to change through growth and reorganization. This new...
Accurately determining food intake remains a challenge in nutrition research. A new study published in Nature Metabolism, introduces a metagenomics-powered approach to accurately track dietary intake...
The AdventHealth Cancer Institute has been recognized in Becker's Hospital Review as one of the top 100 hospitals and health systems in the country for its excellence in oncology.